Biologics Production Transfer Command Leader — Cell Therapies

The mandate

The partner site completed engineering runs but comparability evidence, operator interventions and chain-of-identity exceptions remain distributed across workstreams without one transfer decision. The programme head resigned after a validation slot was missed and clinical supply returned to the constrained origin site. Technical teams now disagree whether the gap is process understanding, analytical sensitivity, execution discipline or governance latency.

The interim starts within seven days for twelve months, covering evidence reset, two engineering campaigns, validation readiness, regulatory-response support, four end-to-end simulations and permanent successor induction. A patient scheduling change, material excursion, analytical discrepancy, identity exception or partner deviation becomes a command-level transfer event. The last seven weeks are protected for handover; the role ends rather than absorbing commercial manufacturing operations.

Exit requires an approved transfer control strategy, critical-parameter and attribute rationale, comparability ledger, intervention taxonomy, trained and observed operators, chain-of-identity exception paths, campaign readiness and named residual-risk owners. The successor must command an unseen late-patient collection, analytical drift and identity mismatch across both sites, reaching a defensible disposition path without the interim’s private judgement.

The leader may stop a campaign that lacks approved readiness evidence, reallocate CHF64 million of authorised transfer funds, replace temporary workstream leads, convene joint deviation decisions and enforce partner escalation windows. Quality alone releases material and owns deviation disposition; Regulatory approves submission positions; clinical teams manage patient commitments. Process changes outside the approved protocol and permanent supplier decisions require council approval.

Clinical-site operations, marketing authorisation strategy, individual batch release, trial design, commercial pricing, long-term partner sourcing and unrelated manufacturing improvement are excluded. The interim cannot trade identity control for schedule, predetermine comparability outcomes, direct regulatory conclusions or treat protocol execution as proof that operators recognise and respond to meaningful process signals.

Why this seat is open

The transfer leader resigned after missed validation exposed fragmented authority across sponsor and partner teams. An experienced command executive is required immediately to convert scattered technical evidence into campaign decisions and patient-safe contingencies while a permanent manufacturing-transfer leader is recruited and tested through live operations.

What you will own

• Reconcile process, analytical, intervention, material and chain-of-identity evidence into one transfer decision ledger.
• Set campaign entry criteria covering facility, method, operator, material, documentation, scheduling and exception readiness.
• Direct joint sponsor-partner governance around deviations, unresolved comparability signals and time-critical patient consequences.
• Protect scarce validation slots by exposing prerequisites, decision dates, fallback positions and accountable evidence owners.
• Allocate authorised transfer resources toward limiting process understanding, analytical and execution constraints.
• Command four simulations involving late collection, courier disruption, identity mismatch, assay drift and partner-system outage.
• Hand command to the successor after independent control of an unfamiliar cross-site patient and comparability event.

Candidate qualifications

• Held executive technology-transfer or manufacturing authority for cell therapies, biologics or other patient-specific products.
• Recovered sponsor-to-partner transfers where comparability, operator intervention and identity controls interacted.
• Directed engineering and validation readiness without trespassing on independent Quality release or regulatory decisions.
• Managed time-critical patient supply through cross-site deviations, analytical uncertainty and constrained manufacturing slots.
• Converted tacit transfer judgement into governed evidence, escalation windows, rehearsals and accountable residual risks.
• Inducted permanent leadership through a live campaign and an unseen identity or comparability disruption.

Non-negotiables

• Available within seven days for Basel command, nine site residencies and four end-to-end simulations.
• Direct cell-therapy or complex-biologics transfer authority is required; project coordination alone is insufficient.
• Will disclose contract manufacturers, analytical laboratories, couriers, therapy developers and regulatory-advisory relationships.
• Will not release batches, predetermine deviations, issue regulatory positions, design trials or select long-term suppliers.

1. 49 words maximum. Describe a biologics transfer where operator intervention, not process specification, became the decisive risk.
2. 49 words maximum. How did you preserve chain of identity during a cross-site exception under patient pressure?
3. 49 words maximum. State your Basel availability and the latest validation recovery you personally commanded.